Facility Deficiencies Drive Rising CRL Rates For CDER Biologics

 
• By Bridget Silverman
  
bioreactor
The complexity of advanced biologic manufacturing can delay US FDA approval. • Source: Shutterstock

More from Manufacturing

More from Compliance